CRNX
Crinetics Pharmaceuticals Inc
$21.35
Earnings Summary
Revenue | $3.13Mn |
Net Profits | $-34.63Mn |
Net Profit Margins | -1105.94% |
Highlights
Crinetics Pharmaceuticals Inc’s revenue jumped +Inf% since last year same period to $3.13Mn in the Q1 2022. On a quarterly growth basis, Crinetics Pharmaceuticals Inc has generated 290345.27% jump in its revenue since last 3-months.
Crinetics Pharmaceuticals Inc’s net profit fell -51.2% since last year same period to $-34.63Mn in the Q1 2022. On a quarterly growth basis, Crinetics Pharmaceuticals Inc has generated -145.12% fall in its net profits since last 3-months.
Crinetics Pharmaceuticals Inc’s net profit margin jumped NaN% since last year same period to -1105.94% in the Q1 2022. On a quarterly growth basis, Crinetics Pharmaceuticals Inc has generated -100.02% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Crinetics Pharmaceuticals Inc post its latest quarter earnings
EPS Estimate Current Quarter | -0.67 |
EPS Estimate Current Year | -0.67 |
Highlights
Crinetics Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.67 - a -15.52% fall from last quarter’s estimates.
Crinetics Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.67.
Key Ratios
Key ratios of the Crinetics Pharmaceuticals Inc post its Q1 2022 earnings
Earning Per Share (EPS) | -0.73 |
Return on Assets (ROA) | -0.27 |
Return on Equity (ROE) | -0.46 |
Dividend Per Share (DPS) | 0 |
Highlights
Crinetics Pharmaceuticals Inc’s earning per share (EPS) fell -5.8% since last year same period to -0.73 in the Q1 2022. This indicates that the Crinetics Pharmaceuticals Inc has generated -5.8% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Crinetics Pharmaceuticals Inc’s return on assets (ROA) stands at -0.27.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Crinetics Pharmaceuticals Inc’s return on equity (ROE) stands at -0.46.
Crinetics Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q1 2022.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2022-05-12 | -0.58 | -0.73 | -25.86% |
Company Information
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, paltusotine (formerly CRN00808), is an oral selective nonpeptide somatostatin receptor type 2 biased agonist undergoing two Phase 2 clinical trials for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 trial in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing CRN04777, an oral nonpeptide somatostatin receptor type 5 (SST5) agonist for hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company's drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company
Organisation | Crinetics Pharmaceuticals Inc |
Headquarters | San Diego, California, United States |
Employees | 93 |
Industry | Health Technology |
CEO | R. Scott Struthers |